Bridge City Capital LLC Sells 20,098 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bridge City Capital LLC lessened its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 21.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 74,373 shares of the medical instruments supplier's stock after selling 20,098 shares during the period. LeMaitre Vascular comprises 1.9% of Bridge City Capital LLC's investment portfolio, making the stock its 10th biggest holding. Bridge City Capital LLC owned about 0.33% of LeMaitre Vascular worth $6,240,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. NBC Securities Inc. purchased a new position in LeMaitre Vascular in the first quarter valued at approximately $36,000. Smartleaf Asset Management LLC boosted its holdings in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC grew its position in shares of LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 117 shares during the last quarter. KBC Group NV raised its stake in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 410 shares in the last quarter. Finally, Huntington National Bank lifted its position in LeMaitre Vascular by 64.9% in the fourth quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock valued at $107,000 after acquiring an additional 455 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital increased their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. Finally, Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $97.83.

LeMaitre Vascular Stock Down 2.1%

Shares of NASDAQ LMAT traded down $1.77 during mid-day trading on Thursday, hitting $81.37. 103,908 shares of the company were exchanged, compared to its average volume of 168,315. The stock has a 50 day simple moving average of $83.75 and a 200-day simple moving average of $90.64. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 44.46, a price-to-earnings-growth ratio of 2.22 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The firm had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company's revenue was up 12.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.44 earnings per share. Analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 40.40%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 18,733 shares of the stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $84.77, for a total value of $1,587,996.41. Following the completion of the transaction, the chief executive officer now directly owns 1,873,651 shares of the company's stock, valued at approximately $158,829,395.27. This trade represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 100,000 shares of company stock worth $8,556,857 over the last three months. 9.50% of the stock is currently owned by corporate insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.